Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02566369 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris
A Phase 3 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,208
- Enrollment target
NCT02566369: Completed Phase 3 study, sponsored by Galderma R&D.
NCT02566369 is a Phase 3 study that has completed, run by Galderma R&D. The registered enrollment target is 1,208 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (56% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02566369, a Phase 3 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,208 participants
- Enrollment target
Study Summary
Assessment of the efficacy and safety of CD5789 (trifarotene) 50μg/g cream applied once daily for 12 weeks in subjects with acne vulgaris.
Primary Outcome
Number of subjects who achieved an Investigator Global Assessment (IGA) score of 1 (almost clear) or 0 (Clear) and at least a 2-grade improvement from Baseline to Week 12.
Interventions
- DRUG Placebo cream
- DRUG CD5789 (trifarotene) 50μg/g cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,208 participants |
| Start Date | 2015-11-30 |
| Est. Completion | 2017-11-14 |
| Phase | Phase 3 |
What the finished NCT02566369 record still lists
NCT02566369 is an interventional study that assigns participants to a tested intervention. Its 1,208 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (56% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo cream is the first listed.
NCT02566369 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02566369 about?
NCT02566369 is a clinical study titled "Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris". Assessment of the efficacy and safety of CD5789 (trifarotene) 50μg/g cream applied once daily for 12 weeks in subjects with acne vulgaris.
What is the current status of trial NCT02566369?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,208 participants. The study started on 2015-11-30. Estimated completion is 2017-11-14.
What interventions are being tested in trial NCT02566369?
The interventions under investigation include: Placebo cream (DRUG), CD5789 (trifarotene) 50μg/g cream (DRUG).
Who is sponsoring clinical trial NCT02566369?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02566369's enrollment target sits among peer trials
1,208 218th of 2000 higher than 1,783 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05946213 · 1,209 participants · Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- NCT04267848 · 1,210 participants · Phase 3
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- NCT06535854 · 1,205 participants · NA
Prevail Global Study
- NCT07223593 · 1,205 participants · Phase 3
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI